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ABSTRACT  16 
Purpose of review: The aim is to review the most recent advances in the evidence supporting the use 17 
of various dietary interventions for the management of IBS. 18 
Recent findings: There is insufficient evidence of the effect of fibres other than psyllium in IBS, while 19 
the recent studies on prebiotics suggest a limited effect in IBS. Recent probiotic trials continue to 20 
provide varying results, with some probiotic strains exhibiting beneficial effects, whereas others show 21 
no effect. Recent trials have also confirmed the clinical effectiveness of a diet low in fermentable 22 
carbohydrates (i.e. low FODMAP diet) in IBS. Although gluten sensitivity has also been recently 23 
investigated, its presence cannot be confirmed yet due to the presence of other potential contributing 24 
compounds in wheat. Studies also suggest a potential beneficial effect of peppermint oil, which 25 
warrants further research.  26 
Summary: It is clear that a low FODMAP diet has a beneficial effect in a majority of patients with IBS. 27 
Probiotics also have great potential in the management of IBS, however, it is still unclear which strains 28 
and doses are the most beneficial. Further research is needed on the effect of different fibres, or 29 
combinations of fibres,  in IBS. 30 
 31 
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INTRODUCTION 36 
Irritable bowel syndrome (IBS) is a chronic functional bowel disorder with a high prevalence and high 37 
patient burden. The definition of IBS has recently been updated in the Rome IV diagnostic criteria as 38 
recurrent abdominal pain associated with two or more of: (i) related to defaecation; (ii) associated 39 
with a change in frequency of stool; or (iii) associated with a change in form (appearance) of stool [1]. 40 
The updated Rome IV diagnostic criteria included four major changes. Firstly it disposed of the term 41 
‘discomfort’ due to ambiguity and variations in perception; secondly it increased the threshold for 42 
frequency of abdominal pain to at least 1 day per week (up from 3 days per month); thirdly ‘related 43 
to defecation’ was used instead of ‘improvement with defecation’ as many do not experience relief 44 
on defecation; and fourthly that the onset of abdominal pain no longer needs to coincide with change 45 
in stool frequency or form [1]. In a survey of 5931 people in the United States, Canada and the United 46 
Kingdom, these updated criteria resulted in a lowering in prevalence of IBS to 5.7% [2]. 47 
Over the past five decades the number of research studies investigating the dietary management of 48 
IBS has increased dramatically, and the focus, size and complexity of interventions has also varied. 49 
Initially, much research investigated dietary fibre in the management of IBS with at least 14 50 
randomised controlled trials (RCTs) [3]. However since the 1990’s probiotics have been increasingly 51 
investigated (at least 36 RCTs) [4] and more latterly, the low FODMAP diet (at least 10 RCTs) [5] (Figure 52 
1). The aim is to review the most recent advances in the evidence supporting the use of various dietary 53 
interventions for the management of IBS. 54 
FIBRE AND PREBIOTICS  55 
The beneficial effect of psyllium fibre in IBS was described in a meta-analysis, reporting significant 56 
improvement IBS symptoms, with a number needed to treat of 7 and with no associated adverse 57 
events [3]. More recently, a RCT of 103 children with IBS demonstrated that psyllium resulted in a 58 
greater reduction in pain frequency compared to placebo, although it did not significantly reduce 59 
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absolute pain frequency or pain severity [6]. However, trials of other fibre types (e.g. bran) have failed 60 
to demonstrate consistent effectiveness, with wide variation in effects [3]. This may reflect differential 61 
effects in different IBS subtypes, for example, a systematic review of seven RCTs demonstrated that 62 
various fibres increased stool frequency and softened stool consistency in constipation [7]. Therefore, 63 
research is needed to determine whether other fibres, or combinations of fibres, may be efficacious 64 
and which IBS subtype may benefit from such intervention(s). 65 
Prebiotics have recently been redefined as ‘substrate that is selectively utilized by host 66 
microorganisms conferring a health benefit” [8]. Three recently published studies have investigated 67 
the effect of prebiotics in IBS. Firstly, IBS-D patients were randomised to receive either a film-forming 68 
reticulated protein with a prebiotic mixture of oligo- and polysaccharides or placebo [9]. At the end of 69 
this study, the percentages of patients with abdominal pain and flatulence were significantly lower in 70 
the active group than in the placebo group [9]. Similarly, in a second double-blind study in 108 IBS 71 
patients, partially hydrolysed guar gum led to a significant improvement in bloating compared with 72 
placebo, however no other gut symptoms or stool output measures were improved [10]. Finally, 73 
another RCT assessed the effect of 5 g/d short-chain fructo-oligosaccharides (FOS) compared to 74 
placebo in 79 IBS patients with rectal hypersensitivity [11]. Although the prebiotic group experienced 75 
a significant reduction in anxiety scores compared to placebo, no differences were found for rectal 76 
discomfort, IBS symptoms, quality of life or gut microbiota composition between the two groups [11], 77 
suggesting that this dose of FOS is not effective for the management of IBS.  78 
To conclude, there is insufficient evidence of the effect of fibres other than psyllium in IBS, primarily 79 
due to lack of robust research studies [3], while the recent studies on prebiotics suggest a limited 80 
effect in IBS. Indeed, there is controversy regarding the therapeutic potential of prebiotics in IBS. 81 
Although prebiotics may partially correct dysbiosis in IBS, there is a growing body of evidence 82 
suggesting that at high doses some prebiotic oligosaccharides (e.g. oligofructose, inulin) may worsen 83 
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IBS symptoms due to their rapid fermentation and colonic gas generation; and is discussed in detail 84 
later in this review. 85 
PROBIOTICS  86 
Probiotics are live microorganisms that, when administered in adequate amounts, confer health 87 
benefits to the host. There has been continued interest in the effect of probiotics in IBS, indeed nine 88 
different systematic reviews of probiotics in IBS have been identified , including trials dating back to 89 
1989 [4] (Figure 1). Evidence from those trials indicated that certain species (e.g. Bifidobacterium) are 90 
more effective on persistence of symptoms or abdominal pain than others (e.g. Escherichia). More 91 
recently, over 10 studies have been published in this area, including ex vivo, animal and human studies.  92 
For example, two recent meta-analyses have investigated the effect of specific probiotic species or 93 
strains; the first one examined the efficacy of B. infantis, provided either as part of a multispecies 94 
probiotic supplement or as single strain B. infantis 35624 in IBS patients [12]. It was found that 95 
multispecies probiotics containing B. infantis strains significantly reduced abdominal pain (SMD 0.22; 96 
95% CI, 0.03–0.41) and bloating (SMD 0.30; 95% CI 0.04–0.56), whereas single strain B. infantis 35624 97 
did not impact IBS symptoms [12]. Another meta-analysis that included two RCTs on the effect of 98 
Saccharomyces cerevisiae CNCM I-3856 in 579 IBS patients showed significant improvements in 99 
abdominal pain (OR 1.5; 95% CI 1.1-2.2) and stool consistency in the probiotic group compared to 100 
placebo; improvements in abdominal pain and stool consistency were also observed in the 101 
constipation-predominant IBS subgroup population. However, no sub-analyses for the other IBS 102 
subgroups (e.g. diarrhoea-predominant) were performed [13]. 103 
As shown in Table 1, three recent RCTs have investigated the effect of other probiotic species and 104 
strains in IBS showing conflicting results [14-16]. One RCT showed that Bifidobacterium longum 105 
NCC3001 improved quality of life, but not symptoms, in IBS and also reduced depression scores, which 106 
were associated with changes in brain activation patterns indicative of reduced limbic reactivity [16].  107 
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Therefore, taken together, the current evidence suggest a potential beneficial effect of specific 108 
probiotic strains in certain IBS symptoms. However, the majority of the studies have considerable 109 
limitations, such as the lack of intention-to-treat analyses and the absence of validated assessment 110 
tools, and as a result caution is needed with the interpretation of such studies.  111 
THE LOW FODMAP DIET  112 
The low FODMAP diet involves the restriction of short-chain fermentable carbohydrates, including 113 
oligosaccharides (inulin-type fructans, galacto-oligosaccharides), disaccharides (lactose), 114 
monosaccharides (fructose in excess of glucose) and polyols. The increasing interest in the low 115 
FODMAP diet over the past decade has been accompanied by an increase in the number and size of 116 
randomised controlled trials and randomised comparative trials of this dietary intervention (Figure 1). 117 
Although at least 10 trials have now been published [5], the current review focusses on only the most 118 
recent advances in the understanding of the clinical effectiveness of the low FODMAP diet and the 119 
mechanisms by which FODMAPs induce symptoms. 120 
Clinical effectiveness of the low FODMAP diet 121 
Although nutrient intervention trials are generally easy to control, designing an appropriate placebo 122 
control in a whole diet trial is challenging. Solutions include feeding studies, which can be tightly 123 
controlled but lack external validity to the clinical setting or sham dietary advice [17]. The first placebo-124 
controlled RCT of low FODMAP dietary advice was recently published comparing outcomes to sham 125 
dietary advice. This was delivered together with or without a probiotic in a 2x2 factorial design trial in 126 
104 IBS patients [18]. Adequate symptom relief was reported in 57% of patients in the low FODMAP 127 
group compared with 38% in the sham diet group (P=0.051), with an odds of symptom relief of 2.18 128 
(P=0.052), while the low FODMAP diet led to significant reductions in abdominal pain, bloating, 129 
flatulence and urgency, and improvements in some components of quality of life [18]. The low 130 
FODMAP diet reduced stool Bifidobacterium species, though these were increased in those taking the 131 
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probiotic suggesting that probiotic co-administration may negate the impact on these species during 132 
the low FODMAP diet [18]. 133 
Two further studies have recently been published comparing the effect of a low FODMAP diet to either 134 
a high FODMAP diet [19] or a low FODMAP diet plus FOS [20]. First, a single-blind RCT showed that 135 
the proportion of responders to the diet was significantly higher in the low FODMAP group (72%) 136 
compared to the high FODMAP group (21%, p<0.009) [19]. However, this study did not include an 137 
intention-to-treat analysis and the use of a high FODMAP diet as a comparator group may actually 138 
exacerbate symptoms, therefore inflating the effect size of the low FODMAP diet. The second study 139 
compared the effectiveness of a low FODMAP diet plus placebo to a low FODMAP diet plus FOS (i.e. a 140 
‘normal FODMAP diet’) in a re-supplementation trial [20]. Significantly more patients reported 141 
symptom relief in the low FODMAP group (80%) compared to the low FODMAP plus FOS group (30%; 142 
p=0.013), and nausea, vomiting and flatulence were significantly lower [20].  143 
Another approach to overcoming control groups in dietary intervention trials is to compare to 144 
standard treatments. In 2016, a RCT compared the effectiveness of 4 week low FODMAP diet to a 145 
standard dietary intervention based on the NICE guidelines in patients with diarrhoea-predominant 146 
IBS (IBS-D) [21]. No difference was found in the percentage of patients with adequate relief of 147 
symptoms between those in the low FODMAP (52%) and the NICE guidelines groups (41%, p=0.31), 148 
although there were significantly more abdominal pain responders in the low FODMAP group (51%) 149 
compared to the NICE guideline group (23%, p=0.008) [21]. Another three-arm RCT compared the 150 
clinical effectiveness of a 6 week low FODMAP diet vs gut-directed hypnotherapy vs a combination of 151 
the low FODMAP diet and hypnotherapy in 74 IBS patients, and found high numbers of responders 152 
but no differences among the groups [22].  153 
Therefore, the low FODMAP diet has been shown to be effective compared to control and as effective 154 
as some other interventions in IBS. However, caution should be exercised in ensuring the restriction 155 
phase of the low FODMAP diet is not continued for long periods and that FODMAPs are reintroduced 156 
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into the diet to tolerance, in order to mitigate impacts on nutrient intake and gut microbiome. There 157 
are as yet no RCT investigating FODMAP reintroduction nor the long term effectiveness of the low 158 
FODMAP diet, however in a recent uncontrolled study of 103 patients, 57% reported adequate 159 
symptom relief 6-18 months after starting FODMAP reintroduction [23].  160 
Mechanisms of action 161 
Few recent studies have attempted to elucidate the mechanisms by which fermentable carbohydrates 162 
may trigger IBS symptoms. A UK study included 29 IBS patients and 29 healthy controls and provided, 163 
on 3 separate occasions, 40 g of either glucose, fructose or inulin in a random order, followed by 164 
magnetic resonance imaging [24]. Fructose increased small-bowel water content, while inulin 165 
increased colonic volume and gas in both patients and controls, but only patients experienced gut 166 
symptoms. Importantly, this highlights similar physiological responses to fermentable carbohydrates 167 
in health and in IBS, implicating elevated visceral hypersensitivity to gas production in the 168 
pathogenesis of IBS symptoms, rather than excess gas production per se [24]. 169 
Beyond reducing small intestinal water and colonic gas, numerous preliminary observations from 170 
clinical trials indicate additional potential mechanisms of action of the low FODMAP diet. In two of the 171 
previously described RCTs, the low FODMAP diet resulted in an eight-fold reduction in urinary 172 
histamine [19], and decreased proinflammatory interleukin (IL) 6 and IL-8, suggesting modulation of 173 
immune activation by the low FODMAP diet [20]. 174 
Alongside an improvement in gut symptoms on the low FODMAP diet, it also exerts a profound impact 175 
on the gut microbiota. Recent studies have confirmed previous findings that a diet low in FODMAPs 176 
leads to low concentrations of Bifidobacteria and higher concentrations of Roseburia and 177 
Ruminococcus [19, 20, 25]. However, the link between such changes in the luminal microenvironment 178 
and changes in gut symptoms is still unclear. 179 
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The low FODMAP diet is a complex, costly and burdensome diet and therefore predicting responses 180 
to the diet would be significant advance in the field. A study of 584 patients with functional bowel 181 
disorders showed that chronic diarrhoea and peak breath methane concentrations to a fructose 182 
challenge positively predicted symptom relief following the low FODMAP diet in those with fructose 183 
intolerance (OR 2.62, p=0.007; OR 1.53, p=0.042), while chronic nausea negatively predicted symptom 184 
relief (OR 0.33, p=0.002) [26]. Furthermore, a Swedish study revealed that gut bacterial profiles of IBS 185 
patients responding to a low FODMAP diet differed from non-responders at baseline [25]. In 186 
particular, bacterial abundance was higher in non-responders compared with responders before and 187 
after intervention, while non-responders had higher ’dysbiosis index’ scores than responders at 188 
baseline. More research is needed until this can be used to select which patients are most likely to 189 
respond to the low FODMAP diet in clinical practice. 190 
GLUTEN-FREE DIET  191 
There is a clear and well documented association between gastrointestinal symptoms in IBS and 192 
dietary gluten, including wheat, barley and rye [27], driving interest in a gluten-free diet (GFD) for the 193 
management of IBS. Recently there have been two randomised double-blind placebo-controlled 194 
gluten re-challenge studies in IBS patients with suspected non-coeliac gluten/wheat sensitivity. In both 195 
studies participants followed a GFD for three [28] or four weeks [29], resulting in symptom response 196 
(defined using different gastrointestinal symptom questionnaires) in 55/77 (71%) [28] and 65/164 197 
(40%) [29], respectively, who then underwent a re-challenge studies.  198 
The re-challenge study undertaken by Ellis et al. involved a seven-day crossover using gluten capsules 199 
as the active challenge [28]. Of those completing the study, 18/53 (34%) experienced worsening of 200 
symptoms during only the gluten challenge. Nonetheless, following the placebo challenge, symptoms 201 
were also induced in a notable number of people suggesting the true gluten challenge effect was likely 202 
to be much less than observed. The re-challenge by Zanwar et al. reported that more participants 203 
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experienced worsening of symptoms when challenged with wheat bread (active challenge, 55.7%) 204 
than with gluten-free bread (placebo challenge, 33.3%, p<0.05) [29].   205 
Despite these supportive findings, gluten sensitivity cannot be confirmed in either study due to the 206 
presence of other potential candidates in the active challenges. For instance the wheat bread 207 
contained several additional components linked with gastrointestinal symptoms including amylase-208 
trypsin inhibitors and fructans [30]. Furthermore, even the gluten-containing capsules used by Ellis et 209 
al. contained other non-gluten proteins and therefore an isolated effect of gluten could not be 210 
measured [28]. 211 
It must also be acknowledge that a GFD may not only present a financial burden but has been linked 212 
with a higher risk of nutritional inadequacies. In fact, a recently published epidemiological study in 213 
more than 110,000 people without coeliac disease found that those with the lowest intakes of gluten 214 
had a higher incidence of coronary heart disease, attributed to their lower intakes of wholegrains [31]. 215 
Taken together, sensitivity to wheat may affect a subgroup of IBS, although identifying the specific 216 
wheat component (fructans, gluten, amylase-trypsin inhibitors), the level of sensitivity and whether 217 
transient or lifelong exclusion is needed warrants further research. 218 
COMPLEMENTARY AND ALTERNATIVE MEDICINE  219 
The variable efficacy of conventional therapies in managing IBS symptoms has drawn attention from 220 
some patients and clinicians to complimentary alternative medicine (CAM). CAMs cover a wide range 221 
of therapies, although few have been tested in robust clinical trials.  222 
In IBS the most convincing evidence for CAM lays with peppermint oil and its active ingredient L-223 
menthol. The benefits of peppermint oil are mainly attributed to its antispasmodic properties, 224 
although it has been linked with several other actions including anti-infective and anti-inflammatory 225 
[32]. A review of a meta-analysis suggests an overall benefit of peppermint oil compared to placebo 226 
for global relief of IBS symptoms (RR 2.23, 95% confidence interval (CI) 1.78-2.81) and for improving 227 
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abdominal pain (RR 2.14, 95% CI 1.64-2.79) [33]. Nonetheless, the overall quality of studies was 228 
acknowledged in the weak-graded clinical guideline recommendations [32].  229 
More recently a four-week, randomised, double-blind, placebo-controlled trial demonstrated a 40% 230 
reduction in Total IBS Symptom Score with peppermint oil compared with 24% in the placebo group 231 
(p=0.03) [33]. Although promising, the generalisability of these results are restricted to a select 232 
population who did not take common medications and supplements.  233 
 234 
There is also growing evidence to support combination CAMs. Recent RCTs have reported greater 235 
reductions in IBS Symptom Severity Scale from curcumin and fennel oil compared with placebo (mean 236 
relative: 50.1 ± 28.9% vs 26.1 ± 30.6%, P<0.001) [34] and between a proprietary mixture of 237 
curcuminoids and essential oils from different Curcuma species, fish oil, peppermint oil, caraway oil 238 
and vitamins B1, B9 and D3 (point change: -113.0 ± 64.9 vs -38.7 ± 64.5, P<0.001) [35].  239 
Although these studies were small and had short durations compared to more rigorously designed 240 
trials needed for Food and Drug Administration approval, the role of CAM in IBS deserves greater 241 
attention in high quality clinical trials. 242 
 243 
FUTURE DIRECTIONS AND CONCLUSION  244 
The growing understanding of the pathophysiology of IBS supports the mechanistic potential of a 245 
wide range of dietary therapies although these largely focus on managing symptoms as opposed to 246 
treating the underlying cause. Nonetheless it is becoming increasingly clear that IBS is a 247 
heterogeneous condition and therefore it is unlikely that one nutrition therapy will benefit all. 248 
Currently the most convincing evidence for management of IBS symptoms is psyllium fibre, 249 
probiotics and a low FODMAP diet, although these have varying effect sizes. In order to progress 250 
dietary management of IBS, research needs to investigate the role of nutrition in targeting the 251 
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underlying cause of IBS. Given the role of the gut microbiota in the pathogenesis of IBS and the 252 
pivotal role diet plays in influencing this, the gut microbiota appears to be an attract target.   253 
 254 
WORD COUNT (max 2500 words): 2,950 255 
KEY POINTS (3-5 key points/sentences summarising the paper) 256 
 Many RCTs have been undertaken confirming that certain probiotics improve symptoms and 257 
quality of life in patients with IBS. However, effect sizes may be relatively small, effects are 258 
strain-specific, and the optimal strain, dose, and administration period remains unclear. 259 
 An increasing number of RCTs have been recently published confirming the clinical 260 
effectiveness of a low FODMAP diet for the management of IBS.  261 
 A landmark mechanistic study revealed fructose increased small-bowel water content and 262 
inulin increased colonic gas in both patients and controls, but only patients experienced gut 263 
symptoms, revealing that visceral hypersensitivity to colonic gas is involved in symptom 264 
induction, rather than excess gas production per se.  265 
 Wheat sensitivity appears to affect a subgroup of IBS, although identifying the specific wheat 266 
component (fructans, gluten, amylase-trypsin inhibitors) and the level of sensitivity warrants 267 
further research. 268 
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Table 1: Recent original randomised, placebo-controlled trials of probiotics in IBS 446 
Study n Diagnosis Dose, genus, species, and strain Form Duration Main findings 
Hod et al, 
2017 [14] 
107 IBS-D 6 × 109 CFU/d L. rhamnosus LR5; 
4 × 109 CFU/d L. casei LC5;  
2 × 109 CFU/d L. paracasei LPC5;  
2 × 109 CFU/d L. plantarum LP3;  
1010 CFU/d L. acidophilus LA1;  
8 × 109 CFU/d B. bifidum BF3;  
2 × 109 CFU/d B. longum BG7;  
4 × 109 CFU/d B. breve BR3;  
2 × 109 CFU/d B. infantis BT1;  
4 × 109 CFU/d S. Thermophiles ST3;  
L. bulgaricus LG1, dose unknown; 
6 × 109 CFU/d Lactococcus lactis SL6. 
Capsule 8 weeks No difference between the probiotic and the placebo groups in pain 
intensity (27.8% vs 46.0% p=0.068), stool consistency (42.6% vs 34.0% 
p=0.423) or overall responder rates (20.4% vs 24.0%, p=0.814).  
No difference was found in high sensitivity C reactive protein 
concentrations between the probiotic (median 1.39; IQR 0.39-2.66 mg/L) 
and the placebo group (median 1.48 mg/L; IQR 0.59-2.86 mg/L, p=0.177). 
No difference was found in faecal calprotectin concentrations between the 
probiotic (median 12.0 μg/g; IQR 7.0-25.8 μg/g) and placebo groups 
(median 23.0 μg/g; IQR 12.0- 74.0 μg/g; p=0.817). 
Pinto-Sanchez 
et al, 2017 
[16] 
44 IBS-D & IBS-M 
with mild to 
moderate anxiety 
or depression. 
B. longum NCC3001; dose is unclear  Powder 6 weeks Significantly more patients in the probiotic group had reduced depression 
scores that in the placebo group (RR 1.98; 95% CI 1.16-3.38; p=0.04). No 
differences in anxiety were found. 
B. longum reduced responses to negative emotional stimuli in multiple 
brain areas, including amygdala and fronto–limbic regions, compared with 
placebo. In the probiotic group, reduced engagement of the amygdala was 
more likely to occur in patients with adequate relief of IBS symptoms than 
in those without it (RR 3.07; 95% CI 0.89-10.59; p=0.03). 
Mezzasalma 
et al, 2016 
[15] 
150 IBS-C Group 1: 
5 × 109 CFU/d L. acidophilus PBS066; 
5 × 109 CFU/d L. reuteri PBS072;  
Group 2: 
5 × 109 CFU/d L. plantarum PBS067; 
5 × 109 CFU/d L. rhamnosus LRH020; 
5 × 109 CFU/d B. lactis BL050. 
Capsule 8 weeks The percentage of responders (a decrease of symptoms of at least 30% 
compared for at least 50% of the intervention period) for abdominal pain, 
bloating, constipation and flatulence was higher in both probiotic groups 
compared to placebo.  
At the end of the intervention, quality of life was significantly improved in 
both probiotic groups (Group 1: 22.2 ± 1.0; Group 2: 22.0 ± 0.8) compared 
to placebo (28.7 ± 1.8; p<0.001). 
IBS: irritable bowel syndrome; IBS-D: diarrhoea-predominant IBS; IBS-C: constipation-predominant IBS; IBS-M: mixed-type IBS; IQR: interquartile range; RR: relative risk; B.: Bifidobacterium; L.: 447 
Lactobacillus; S.: Streptoc 448 
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 449 
Figure 1: Trends in dietary intervention trials in irritable bowel syndrome. A scatter plot of the year 450 
of publication and sample size of randomised controlled/comparative trials of fibre, probiotics and the 451 
low FODMAP diet over the past four decades.  452 
This figure indicates a primary focus on dietary fibre during the last millennium, which has now very 453 
much declined, and has been replaced by a greater focus on probiotic research in the 2000’s and by 454 
trials of the low FODMAP diet in the 2010’s. In general, the increase in trials of a specific dietary 455 
intervention has been accompanied by a steady increase in sample sizes of these trials. The individual 456 
studies depicted in this scatter plot are obtained from recent reviews and systematic reviews on fibre 457 
[3], probiotics [4] and the low FODMAP diet [5], and the sample size of cross-over trials is doubled for 458 
comparability.   459 
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